LaBarre Michael J.'s Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Jun 20, 2024
- Accession no.
- 0001415889-24-017625
- Filed
- Jun 20, 2024
- Trade date
- Jun 18, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $494.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBarre Michael J.CIK 0001507174 | Officer (SVP, CHIEF TECHNICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 18, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $8.11 | +$81,100 | 178,176 | Direct | |
| Jun 18, 2024 | Common Stock | SSaleDisposed | −10,000 | $49.43 | −$494,300 | 168,176 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 18, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 11,715 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.